Your email has been successfully added to our mailing list.

×
0 0 0 0 0 1.02005012531328 1.25564411027569 1.19348370927318
Stock impact report

Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

Deciphera Pharmaceuticals, Inc. (DCPH) 
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: deciphera.com/investor-relations
Company Research Source: Business Wire
- INVICTUS Achieved Primary Endpoint, Ripretinib Significantly Improved Progression Free Survival (PFS) Versus Placebo in Patients with Fourth-line and Fourth-line Plus GIST -- Median PFS for Ripretinib of 6.3 Months Versus Placebo of 1.0 Month; Hazard Ratio of 0.15, p- Company Expects to Submit an NDA to the FDA in 1Q 2020 for the Treatment of Patients with Advanced GIST who have Received Prior Treatment with Imatinib, Sunitinib and Regorafenib -- Company to Host Conference Call Today at 8:00 AM ET - WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced positive top-line data from the INVICTUS pivotal Phase 3 clinical study of ripretinib, a broad-spectrum KIT and PDGFRa inhibitor, in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST).“There is a dire unmet need for new therapies that can deliver effec Show less Read more
Impact Snapshot
Event Time:
DCPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for DCPH alerts
Opt-in for
DCPH alerts

from News Quantified
Opt-in for
DCPH alerts

from News Quantified